Monoclonal Antibody Market Report – Likely To Witness Decent Growth In Future

Monoclonal antibody or mAb/moAb is an antibody which is mono-specific and produced by single clone of cells. It has brought revolutionary change in pharmaceutical and biotechnology sectors. The monoclonal antibody market has recorded over USD 80 billion in 2013. Monoclonal antibodies are majorly used to cure cancer and other diseases, such as inflammatory and autoimmune diseases.

Improvements in technology, rising prevalence of cancer and increasing research and development in genomics are likely to propel demand for the monoclonal antibody market. However, high costs involved in the development of monoclonal antibodies and huge time in developing them are expected to hamper the market.

The pharmaceutical and biotechnology sectors are estimated to propel demand for the monoclonal antibody market. This is due to expansion in these sectors across the globe and rising use of monoclonal antibodies for cancer treatment. The monoclonal antibody market can be segmented into diagnostics, treatments and geographies. On the basis of diagnostics, the market is divided into detection of toxins, pregnancy test kits and AIDS diagnostics.

The monoclonal antibody market, on the basis of treatments, can be divided into autoimmune diseases, cardiovascular diseases, ophthalmic indications, cancers, infectious diseases and respiratory diseases. Geographically, the monoclonal antibody market can be divided into four major regions, including North America, Asia Pacific, Europe and ROW (rest of the world).

North America dominated the market. This was owing to improved technology and rising pharmaceuticals sector in the region. This region was followed by Europe. Asia Pacific has shown steady growth in the monoclonal antibody market due to governmental funds and rising population.